Antimüllerian hormone levels are lower in BRCA2 mutation carriers

BRCA2 mutation carriers have antimullerian hormone (AMH) levels that are significantly lower than healthy low-risk control women and have increased odds of having low AMH levels.

Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine
Published
Like Comment

Volume 107, Issue 5, Pages 1256–1265.e6

Authors:

Lauren Johnson, M.D., M.S.C.E, Mary D. Sammel, Sc.D., Susan Domchek, M.D., Allison Schanne, B.A., Maureen Prewitt, B.S.N., Clarisa Gracia, M.D., M.S.C.E.

Abstract:

Go to the profile of Fertility and Sterility

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. 

Comments

Go to the profile of Dr Elena Kontogianni
Dr Elena Kontogianni
over 4 years ago
Should we conceded oocyte freezing to BRCA2 carriers? Is their fertility in general lower than brca2 non-carriers?